GT Biopharma, Inc. — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 15/100
What the filing says
GT Biopharma (market cap ~$8.6M) filed Form 8-K on 2026-09-25 for period ending 2026-09-22. The filing references Item 8.01 (Other Events) and Item 9.01 (Financial Statements/Exhibits) but the actual substantive disclosure text is not provided in the metadata—only file names and XBRL formatting information are visible. No material facts, dollar amounts, counterparties, or business developments can be extracted from this submission summary.
Why this rating
Filing metadata only; no substantive disclosure accessible. Unable to assess materiality without actual 8-K content.
Extracted items
- 8.01 other event
- 9.01 exhibits
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.